“Treat to Persist”, una profundización del “Treat to Target”
Resumen
El tratamiento de la artritis reumatoidea (AR), ha evolucionado considerablemente en los últimos años, resultando en una mejoría notable en la capacidad funcional, calidad y expectativa de vida de los pacientes1. Esta mejoría no solo se debe al desarrollo de más y mejores medicaciones, sino principalmente a la internalización por parte de la mayoría de los reumatólogos del concepto de treat to target (T2T) o tratamiento dirigido al objetivo2. El T2T establece 4 principios básicos, que incluyen: A) El tratamiento de la artritis reumatoidea debe estar basado en una decisión conjunta del reumatólogo y el paciente, B) El objetivo primario del trata-miento de la AR es favorecer una buena calidad de vida a largo plazo, a través del control de los síntomas, prevención del daño estructural, normalización de la capacidad funcional y participación social del paciente, C) La supresión de la inflamación es la principal manera de lograr estos objetivos, D) El tratamiento hacia un objetivo, evaluando la actividad de la enfermedad y ajustando el tratamiento en consecuencia, mejora la evolución de los pacientes con AR.Citas
I. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommenda-tions for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 upda-te. Ann Rheum Dis 2020;79:684–98.
II. Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an in-ternational Task force. Ann Rheum Dis 2016;75:3–15.
III. Robinson PC, Taylor WJ. Time to treatment in rheumatoid arthri-tis: factors associated with time to treatment initiation and urgent triage assessment of general practitioner referrals. J Clin Rheuma-tol2010;16:267–73
IV. Kyburz D, Gabay C, Michel BA, et al. The long-term impact of early treatment of rheumatoid arthritis on radiographic progression: a population-based cohort study. Rheumatology 2011;50:1106–10.
V. Schipper LG, Vermeer M, Kuper HH, et al. A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual caretreatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monito-ring registry. Ann Rheum Dis 2012;71:845–50.
VI. van Eijk IC, Nielen MM, van der Horst-Bruinsma I, et al. Aggressive therapy in patients with early arthritis results in similar outcome compared with conventional care: the STREAM randomized trial. Rheumatology 2012;51:686–94.
VII. Stoffer MA, Schoels MM, Smolen JS, et al. Evidence for treating rheu-matoid arthritis to target: results of a systematic literature search update. Ann Rheum Dis doi:10.1136/annrheumdis-2015-207526.
VIII. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Kerstens PJ, et al. DAS-driven therapy versus routine care in patients with recent-on-set active rheumatoid arthritis.Ann Rheum Dis 2010;69:65–9.
IX. Vermeer VM, Kuper HH, Bernelot Moens HJ,Drossaers-Bakker KW, et al: Sustained Beneficial Effects of a Protocolized Treat-to-Target Strategy in Very Early Rheumatoid Arthritis: Three-Year Results of the Dutch Rheumatoid Arthritis Monitoring Remission Induction Cohort. Arthritis Care Res 2013;65:1219-26
X. Aga AB ,Lie E,Uhlig T,et al: Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past de-cade: results from the NOR-DMARD study 2000–2010. Ann Rheum Dis 2015;74:381–388.
XI. Solomon, DH, Reed G, Kremer JM, et al: Disease Activity in Rheu-matoid Arthritis and the Risk of Cardiovascular Events. Arhritis Rheumatol DOI 10.1002/art.39098
XII. Pincus T , Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK:Severe functional declines, work disability, and increased mortality in studied over nine years seventy-five rheumatoid ar-thritis patients. Arthritis Rheumatol 1984;27:864-72
XIII. Gómez-Reino JJ, Rodríguez-LozanoC, Campos-Fernández C et al Ann Rheum Dis 2012;71:382–385.
XIV. Blum MA, Koo D, Doshi JA (2011) Measurement and rates of persis-tence with and adherence to biologics for rheumatoid arthritis: a systematic review. Clin Ther 33(7):901–913
XV. Dalén J, Axel Svedbom A, Black CM, et al: Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs asso-ciated with non-persistence. Rheumatol Int DOI 10.1007/s00296-016-3423-5
XVI. van den Bemt BJ, van Lankveld WG. How can we improve adheren-ce to therapy by patients with rheumatoid arthritis? Nat Clin Pract Rheu¬matol. 2007;3(12):681.
XVII. Kavanaugh A, Lee SJ, Curtis JR, Greenberg JD, Kremer JM, Soto L, et al. Discontinuation of tumour necrosis factor inhibitors in patients with. rheumatoid arthritis in low-disease activity: persistent bene-fits: data from the Corrona registry. Ann Rheum Dis 2015;74:1150–5.
XVIII. Flouri I, Markatseli TE, Voulgari PV, et al. Comparative effective-ness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival. Semin Arthritis Rheum. 2014;43(4):447-457.
XIX. Ebina K, Hashimoto M, Yamamoto W, et al. Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort study. PLoS One. 2019;14(5):e0216624.
Derechos de autor 2020 A nombre de los autores. Derechos de reproducción: Sociedad Argentina de Reumatología
Esta obra está bajo licencia internacional Creative Commons Reconocimiento-NoComercial-SinObrasDerivadas 4.0.
